Corrigendum to Prevention of tobacco carcinogen-induced lung cancer in female mice using Antiestrogens. [Carcinogenesis 33, 11, (2012) 2181-2189 doi:10.1093/carcin/bgs260];Prevention of tobacco carcinogen-induced lung cancer in female mice using antiestrogens

Carcinogenesis

Volumn 33, Issue 11, 2012, Pages 2181-2189

  Stabile, Laura P ^a   Rothstein, Mary E ^a   Cunningham, Diana E ^b   Land, Stephanie R ^c   Dacic, Sanja ^a   Keohavong, Phouthone ^a   Siegfried, Jill M ^a  

^a UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^b UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 (METHYLNITROSAMINO) 1 (3 PYRIDYL) 1 BUTANONE; ANASTROZOLE; ANDROSTENEDIONE; AROMATASE; CARCINOGEN; ESTROGEN; ESTROGEN RECEPTOR BETA; FULVESTRANT; KI 67 ANTIGEN; PLACEBO;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER GROWTH; CELL PROLIFERATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG MECHANISM; DRUG POTENTIATION; ENZYME SUBSTRATE; FEMALE; LUNG CANCER; LUNG CARCINOGENESIS; MACROPHAGE; MOUSE; NONHUMAN; PRECANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR UPREGULATION; TOBACCO; TUMOR CELL;

EID: 84868629916     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgt071     Document Type: Erratum

References (49)

1. Stabile, L.P. et al. (2011) Combined analysis of estrogen receptor beta-1 and progesterone receptor expression identifies lung cancer patients with poor outcome. Clin. Cancer Res., 17, 154-164.
2. Schwartz, A.G. et al. (2005) Nuclear estrogen receptor beta in lung cancer: expression and survival differences by sex. Clin. Cancer Res., 11, 7280-7287.
3. Hershberger, P.A. et al. (2009) Estrogen receptor beta (ERbeta) subtypespecific ligands increase transcription, p44/p42 mitogen activated protein kinase (MAPK) activation and growth in human non-small cell lung cancer cells. J. Steroid Biochem. Mol. Biol., 116, 102-109.
4. Stabile, L.P. et al. (2002) Human non-small cell lung tumors and cells derived from normal lung express both estrogen receptor alpha and beta and show biological responses to estrogen. Cancer Res., 62, 2141-2150.
5. Stabile, L.P. et al. (2005) Combined targeting of the estrogen receptor and the epidermal growth factor receptor in non-small cell lung cancer shows enhanced antiproliferative effects. Cancer Res., 65, 1459-1470.
6. Hershberger, P.A. et al. (2005) Regulation of endogenous gene expression in human non-small cell lung cancer cells by estrogen receptor ligands. Cancer Res., 65, 1598-1605.
7. Weinberg, O.K. et al. (2005) Aromatase inhibitors in human lung cancer therapy. Cancer Res., 65, 11287-11291.
8. Mah, V. et al. (2007) Aromatase expression predicts survival in women with early-stage non small cell lung cancer. Cancer Res., 67, 10484-10490.
9. Ganti, A.K. et al. (2006) Hormone replacement therapy is associated with decreased survival in women with lung cancer. J Clin Oncol, 24, 59-63.
10. Chlebowski, R.T. et al. (2009) Oestrogen plus progestin and lung cancer in postmenopausal women (Women's Health Initiative trial): a post-hoc analysis of a randomized controlled trial. Lancet, 374, 1243-1251.
11. Bouchardy, C. et al. (2011) Lung cancer mortality risk among breast cancer patients treated with anti-estrogens. Cancer, 117, 1288-1295.
12. Slatore, C.G. et al. (2010) Lung cancer and hormone replacement therapy: association in the vitamins and lifestyle study. J. Clin. Oncol., 28, 1540-1546.
13. Coombes, R.C. et al. (2004) A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N. Engl. J. Med., 350, 1081-1092.
14. Cuzick, J. et al. (2010) Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial. Lancet Oncol., 11, 1135-1141.
15. Goss, P.E. et al. (2011) Exemestane for breast-cancer prevention in postmenopausal women. N. Eng. J. Med., 364, 2381-2391.
16. Cuzick, J. (2005) Aromatase inhibitors for breast cancer prevention. J. Clin. Oncol., 23, 1636-1643.
17. Stabile, L.P. et al. (2006) Transgenic mice overexpressing hepatocyte growth factor in the airways show increased susceptibility to lung cancer. Carcinogenesis, 27, 1547-1555.
18. Chumsri, S. et al. (2011) Aromatase inhibitors and xenograft studies. Steroids, 76, 30-35.
19. Foster, P.A. et al. (2008) A new therapeutic strategy against hormonedependent breast cancer: the preclinical development of a dual aromatase and sulfatase inhibitor. Clin. Cancer Res., 14, 6469-6477.
20. Stabile, L.P. et al. (2008) Therapeutic targeting of human hepatocyte growth factor with a single neutralizing monoclonal antibody reduces lung tumorigenesis. Mol. Cancer Ther., 7, 1913-1922.
21. Meireles, S.I. et al. (2010) Early changes in gene expression induced by tobacco smoke: evidence for the importance of estrogen within lung tissue. Cancer Prev. Res., 3, 707-717.
22. Mor, G. et al. (1998) Macrophages, estrogen and the microenvironment of breast cancer. J. Steroid Biochem. Mol. Biol., 67, 403-411.
23. Subbaramaiah, K. et al. (2011) Obesity is associated with inflammation and elevated aromatase expression in the mouse mammary gland. Cancer Prev. Res., 4, 329-346.
24. Lambert, K.C. et al. (2004) Estrogen receptor-α deficiency promotes increased TNF-a secretion and bacterial killing by murine macrophages in response to microbial stimuli in vitro. J. Leukocyte Biol., 75, 1166-1172.
25. Piesta, A. et al. (2009) The influence of mating on estrogen receptor alpha protein level in spleen and uterine macrophages in female mice. Reproductive Biol., 9, 225-240.
26. Calippe, B. et al. (2008) Chronic estradiol administration in vivo promotes the proinflammatory response of macrophages to TLR4 activation: involvement of the phosphatidylinositol kinase pathway. J. Immunol., 180, 7980-7988.
27. Kawano, N. et al. (2004) Identification and localization of estrogen receptor a- and b-positive cells in adult male and female mouse intestines at various estrogen levels. Histochem. Cell Biol., 121, 399-405.
28. Kramer, P.R. et al. (2002) 17-Beta-estradiol regulates expression of genes that function in macrophage activation and cholesterol homeostasis. J. Steroid Biochem. Mol. Biol., 81, 203-216.
29. Subbaramaiah, K. et al. (2009) Oestrogen modulates human macrophage apoptosis via differential signaling through oestrogen receptor-α and β. J. Cell Mol. Med., 13, 2317-2329.
30. Lu, Q. et al. The effects of aromatase inhibitors and antiestrogens in the nude mouse model. Breast Cancer Res. Treat, 50, 63-71.
31. Marquez-Garban, D.C. et al. (2009) Targeting aromatase and estrogen signaling in human non-small cell lung cancer. Ann. NY Acad. Sci., 1155, 194-205.
32. Fujimoto, J. et al. (2010) Comparative functional genomics analysis of NNK tobacco-carcinogen induced lung adenocarcinoma development in Gprc5aknockout mice. PloS One, 5: e11847. doi:10.1371/journal.pone.0011847.
33. Riely, G.J. et al. (2008) Frequency and distinctive spectrum of KRAS mutations in never smokers with lung adenocarcinoma. Clin. Cancer Res., 14, 5731-5734.
34. Yoneya, T. et al. (2009) Effects of CH4893237, a new orally active estrogen receptor downregulator, on breast cancer xenograft models with low serum estrogen levels. Oncol. Rep., 21, 747-755.
35. Hoffman, J. et al. (2004) Characterization of new estrogen receptor destabilizing compounds: effects on estrogen-sensitive and tamoxifen-resistant breast cancer. J. Natl Cancer Inst., 96, 210-208.
36. Jelovac, D. et al. (2005) Additive antitumor effect of aromatase inhibitor and antiestrogen fulvestrant in a postmenopausal breast cancer model. Cancer Res., 65, 5439-5444.
37. Macedo, L.F. et al. (2008) Combination of anastrozole with fulvestrant in the intratumoral aromatase xenograft model. Cancer Res., 68, 3516-3522.
38. Mah, V. et al. (2011) Expression levels of estrogen receptor beta in conjunction with aromatase predict survival in non-small cell lung cancer. Lung Cancer, 74, 318-325.
39. Ramnath, N. et al. (2007) Hormone replacement therapy as a risk factor for non-small cell lung cancer: results of a case-control study. Oncology, 73, 305-310.
40. Schwartz, A.G. et al. (2007) Reproductive factors, hormone use, estrogen receptor expression and risk of non-small cell lung cancer in women. J. Clin. Oncol., 25, 5785-5792.
41. Harman, S.M. et al. (2011) Timing and duration of menopausal hormone treatment may affect cardiovascular outcomes. Am. J. Med., 124, 199-205.
42. Berstein, L.M. et al. (1998) Ability of lymphocytes infiltrating breast-cancer tissue to convert androstenedione. Int. J. Cancer, 77, 485-487.
43. Berstein, L.M. et al. (2002) Aromatase (CYP19) expression in tumor-infiltrating lymphocytes and blood mononuclears. J. Cancer Res. Clin. Oncol., 128, 173-176.
44. Coussens, L.M. et al. (2002) Inflammation and cancer. Nature, 420, 860-867.
45. Leary, A. et al. (2006) Combination therapy with aromatase inhibitors: the next era of breast cancer treatment? Br. J. Cancer, 95, 661-666.
46. Bergh, J. et al. (2012) FACT: an open-label, randomized phase III study of fulvestrant and anastrozole in combination compared with anastrozole alone as first-line therapy for patients with receptor-positive postmenopausal breast cancer. J. Clin. Oncol., 30, 1919-1925.
47. Traynor, A.M. et al. (2009) Pilot study of gefitinib and fulvestrant in the treatment of post-menopausal women with advanced non-small cell lung cancer. Lung Cancer, 64, 51-59.
48. Garon, E.B. et al. (2011) Randomized multicenter phase II study of erlotinib (E) + fulvestrant (F) in previously treated advanced non-small cell lung cancer (NSCLC). J. Clin. Oncol., 29, (suppl; abstr TPS216).
49. McLaughlin, B.T. et al. (2011) A phase II randomized trial of anastrozole (A) and fulvestrant (F) as consolidation therapy in postmenopausal women with advanced non-small cell lung cancer who have received first-line platinum-based chemotherapy with or without bevacizumab. J. Clin. Oncol., 29, (suppl; abstr TPS212).